Human Vaccines & Immunotherapeutics(formerly Human Vaccines)
Volume 8, Issue 9  September 2012
http://www.landesbioscience.com/journals/vaccines/toc/volume/8/issue/8/

Research Paper
Modeling the economic value of a Chagas’ disease therapeutic vaccine
http://dx.doi.org/10.4161/hv.20966
Authors: Bruce Y. Lee, Kristina M. Bacon, Angela R. Wateska, Maria Elena Bottazzi, Eric Dumonteil and Peter J. Hotez

Abstract:
The health burden of Chagas’ disease (resulting from Trypanosoma cruzi infection) in Latin America (estimated to outweigh that of malaria by 5-fold and affect 2–6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent infection progression to severe disease. Our economic model for a Chagas’ therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk, and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the onset of cardiomyopath